Home » Stocks » EDIT

Editas Medicine, Inc. (EDIT)

Stock Price: $43.86 USD -0.90 (-2.01%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $42.90 -0.96 (-2.19%) Feb 26, 7:59 PM
Market Cap 2.76B
Revenue (ttm) 90.73M
Net Income (ttm) -115.98M
Shares Out 58.61M
EPS (ttm) -1.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $43.86
Previous Close $44.76
Change ($) -0.90
Change (%) -2.01%
Day's Open 45.00
Day's Range 42.33 - 46.24
Day's Volume 3,043,288
52-Week Range 14.01 - 99.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
24/7 Wall Street - 2 days ago

With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.

Other stocks mentioned: ABNB
GuruFocus - 2 days ago

ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.

Other stocks mentioned: AMZN, ARKK, CGEN
Zacks Investment Research - 2 days ago

Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.

The Motley Fool - 5 days ago

After a huge run-up in valuation, investors are a little spooked.

The Motley Fool - 1 week ago

Turnover at the top of a company can be troubling. But it can sometimes be a good thing.

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on T...

Zacks Investment Research - 1 week ago

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 week ago

In a field that's becoming more crowded, what will set Editas apart?

Zacks Investment Research - 1 week ago

On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.

Zacks Investment Research - 2 weeks ago

Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.

Zacks Investment Research - 2 weeks ago

As more young investors take up day trading, I have a recipe for long-term wealth creation

Other stocks mentioned: ARKK, GME, NVDA, TSLA
Zacks Investment Research - 2 weeks ago

As more young investors take up day trading, I have an important recipe for long-term wealth creation.

Other stocks mentioned: ARKK, GME, NVDA, TSLA
The Motley Fool - 2 weeks ago

Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.

The Motley Fool - 3 weeks ago

Which of these two hot gene therapy stocks is the better buy?

Other stocks mentioned: CRSP
Zacks Investment Research - 3 weeks ago

In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.

Forbes - 1 month ago

Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Ou...

Other stocks mentioned: NTLA
The Motley Fool - 1 month ago

Could this maverick biotech discover the cure for several debilitating rare diseases?

Zacks Investment Research - 1 month ago

In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.

Forbes - 1 month ago

Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to ...

The Motley Fool - 1 month ago

It's a big bet but not a big gamble.

Other stocks mentioned: GH, ISRG, TDOC, VRTX, XBI
The Motley Fool - 1 month ago

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Other stocks mentioned: CRSP, JNJ, SPY, VRTX, VTI
Seeking Alpha - 1 month ago

Sana Biotechnology Seeks $150 Million U.S. IPO

Other stocks mentioned: BMY, CRSP, GILD, JNJ, NVO, NVS
InvestorPlace - 1 month ago

There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology comp...

The Motley Fool - 1 month ago

All four biotechs announced the pricing of stock offerings.

Other stocks mentioned: CTMX, INO
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 s...

GuruFocus - 1 month ago

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...

Other stocks mentioned: BEAM, CRSP, NTLA, SWTX
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of ...

Zacks Investment Research - 1 month ago

Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD.

24/7 Wall Street - 1 month ago

Commentary from Ark Invest: We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week.

Other stocks mentioned: AVAV, GBTC, NNDM, SSYS, TREE
Zacks Investment Research - 1 month ago

Editas Medicine (EDIT) closed at $76.14 in the latest trading session, marking a +0.29% move from the prior day.

InvestorPlace - 1 month ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: BEAM, CLLS, CLXT, CRSP, NTLA, SGMO
Forbes - 1 month ago

Despite a stellar 4x rise since the March 23 lows of last year, at the current price of around $73 per share we believe Editas Medicine, a biotechnology company focused on developing treatment...

The Motley Fool - 1 month ago

Just because they did it in 2020 doesn't mean they won't outrun the market again in the new year.

Other stocks mentioned: BNTX, SDC
Zacks Investment Research - 1 month ago

The FDA clears the initiation of the safety phase of Editas' (EDIT) early-stage study on investigational gene-editing therapy EDIT-301 for treating sickle cell disease. Shares down.

The Motley Fool - 1 month ago

One of the biotech's top executives is leaving.

Forbes - 1 month ago

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...

Other stocks mentioned: NTLA, CRSP
GlobeNewsWire - 1 month ago

Details progress on ocular programs, including EDIT-101 Phase 1/2 BRILLIANCE trial updates

GlobeNewsWire - 1 month ago

EDIT-301 is in development as a best-in-class, durable medicine for people living with sickle cell disease EDIT-301 is in development as a best-in-class, durable medicine for people living wit...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its Chief Scientific Officer, Charles Albright,...

GuruFocus - 1 month ago

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Other stocks mentioned: CRSP, NTLA
Investors Business Daily - 1 month ago

Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The...

Other stocks mentioned: NTLA, CRSP
24/7 Wall Street - 1 month ago

Over halfway through the trading day on Thursday, and the broad markets are making a run into the afternoon.

Other stocks mentioned: FDX, LMT, ROKU, ACI, ARCT, BIG, CME, DDD, DPZ
Zacks Investment Research - 1 month ago

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Other stocks mentioned: CRSP, NTLA
The Motley Fool - 1 month ago

Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.

Other stocks mentioned: BBIO, FATE
GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th ...

Zacks Investment Research - 1 month ago

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Other stocks mentioned: CBAY, MRNS, NTLA, VRTX
The Motley Fool - 1 month ago

Big drugmakers could be attracted to these smaller players with promising pipelines.

Other stocks mentioned: TBIO, BLUE
The Motley Fool - 2 months ago

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Other stocks mentioned: CRSP, NTLA
Investors Business Daily - 2 months ago

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Other stocks mentioned: NTLA, QURE
Business Insider - 2 months ago

Shares of Editas Medicine, a genome editing company that utilizes CRISPR technology, soared as much as 50% to new all-time highs on Monday. There was no official news from the company to expla...

About EDIT

Editas Medicine operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary genome editing platform based on CRISPR technology, which includes CRISPR/Cas9, CRISPR/Cas12a, and engineered forms of both of these CRISPR systems to target genetically addressable diseases and therapeutic areas. It also develops EDIT-101, which is in Phase 1/2 clinical trial for the treatment of Leber Congenital Amaurosis type 10, a gene... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
Cynthia Collins
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
EDIT
Full Company Profile

Financial Performance

In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 54.83, which is an increase of 25.01% from the latest price.

Price Target
$54.83
(25.01% upside)
Analyst Consensus: Buy